Literature DB >> 30624183

Monoclonal gammopathy of undetermined significance: A primary care guide.

Jack Khouri1, Christy Samaras2,3, Jason Valent2,3, Alex Mejia Garcia2, Beth Faiman4, Saveta Mathur2, Kimberly Hamilton2, Megan Nakashima5,6, Matt Kalaycio7,8,9.   

Abstract

Monoclonal gammopathy of undetermined significance (MGUS) is commonly diagnosed in outpatients being worked up for an array of clinical concerns. It carries a risk of progression to myeloma and other lymphoproliferative disorders that, albeit low (1% per year), warrants regular follow-up. Patients with MGUS can be risk-stratified on the basis of the amount and type of their monoclonal protein as well as whether they have an abnormal light-chain ratio. Here, we provide a guide to the diagnosis, workup, and management of MGUS.
Copyright © 2019 Cleveland Clinic.

Entities:  

Year:  2019        PMID: 30624183     DOI: 10.3949/ccjm.86a.17133

Source DB:  PubMed          Journal:  Cleve Clin J Med        ISSN: 0891-1150            Impact factor:   2.321


  2 in total

Review 1.  Cancer Immunoprevention: Current Status and Future Directions.

Authors:  Mahsa Keshavarz-Fathi; Nima Rezaei
Journal:  Arch Immunol Ther Exp (Warsz)       Date:  2021-02-27       Impact factor: 4.291

2.  Dual anti-neutrophil cytoplasmic antibody and anti-glomerular basement membrane antibody-positive crescent glomerulonephritis in a patient with monoclonal gammopathy of undetermined significance: A case report.

Authors:  Xiaoli Li; Yunfei Hao; Rong Xue; Xueting Qi; Zhigang Ma
Journal:  Medicine (Baltimore)       Date:  2019-02       Impact factor: 1.817

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.